ACR Meeting Abstracts

ACR Meeting Abstracts

Abstract Number: 1536

Comparing Abatacept to Adalimumab, Etanercept and Infliximab As First Line Agents in Patients with Rheumatoid Arthritis. Experience from the Rhumadata® Clinical Database and Registry

Denis Choquette1, Louis Bessette2, Isabelle Fortin3, Boulos Haraoui1, Jean Pierre Pelletier1, Jean-Pierre Raynauld1, Marie-Anaïs Rémillard4, Diane Sauvageau1, Edith Villeneuve1 and Louis Coupal1, 1Rheumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada, 2Rheumatology, Centre d’ostéoporose et de rhumatologie de Québec (CORQ), Québec, QC, Canada, 3Centre de rhumatologie de l'est du Québec (CREQ), Rimouski, QC, Canada, 4Rhumatology, Institut de rhumatologie de Montréal (IRM), Montréal, QC, Canada

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: , ,

Session Information

Session Title: Rheumatoid Arthritis - Small Molecules, Biologics and Gene Therapy: Novel therapies, Biosimilars, Strategies and Mechanisms in Rheumatoid Arthritis

Session Type: Abstract Submissions (ACR)

Background/Purpose: The order of use of biologic agents is still a question for debate. Phase III trial data in MTX-IR patients show comparable efficacy results across biologic agents and limited head-to-head studies have been published. Registries offer a unique opportunity to prospectively monitor the effectiveness of these agents in a clinical setting. We aim to assess if patients with rheumatoid arthritis (RA) treated with abatacept after failure of a first line agent (MTX-IR) have a different drug survival rate than patients similarly treated with adalimumab, etanercept or infliximab.

Methods: RA patients prescribed a first biologic agent after January 1st2007 were included in the present analysis. We extracted a cohort formed of all patients prescribed abatacept (ABA), adalimumab (ADA), etanercept (ETA) or infliximab (INF) as their first biologic agent. Baseline demographics for this cohort included age, disease duration, HAQ-DI, fatigue and pain visual analog scale evaluation (VAS), TJC, SJC, DAS 28 ESR and SDAI. Person-years of treatment were also compared across biologic agents. Statistical analysis was performed using SAS version 9.3. RHUMADATA® is a clinical database and registry used daily in clinical practice at the IRM, CORQ and CREQ.

Results: A total 340 patients were included in the cohort. No clinically significant differences in baseline characteristics were noted between treatment groups. The 5 year retention rate of ABA, ADA, ETA and INF post MTX failure were 64%, 40%, 49% and 42% without significant statistical differences (Log-Rank p=0.29).

Conclusion: Abatacept, adalimumab, etanercept and infliximab after MTX failure have similar 5-years retention rates.

Disclosure:

D. Choquette,
None;

L. Bessette,
None;

I. Fortin,
None;

B. Haraoui,

AbbVie,

2,

AbbVie,

5,

Amgen,

2,

Amgen,

5,

Bristol-Myers Squibb,

2,

Bristol-Myers Squibb,

5,

Janssen Pharmaceutica Product, L.P.,

2,

Janssen Pharmaceutica Product, L.P.,

5,

Pfizer Inc,

2,

Pfizer Inc,

5,

Roche Pharmaceuticals,

2,

Roche Pharmaceuticals,

5,

UCB,

2,

UCB,

5;

J. P. Pelletier,
None;

J. P. Raynauld,
None;

M. A. Rémillard,
None;

D. Sauvageau,
None;

E. Villeneuve,
None;

L. Coupal,
None.

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/comparing-abatacept-to-adalimumab-etanercept-and-infliximab-as-first-line-agents-in-patients-with-rheumatoid-arthritis-experience-from-the-rhumadata-clinical-database-and-registry/